The triple combo era in cystic fibrosis is here thanks to Vertex’ new OK. Five months ahead of schedule, the FDA green-lighted Trikafta for the treatment of CF patients over the age of 12 with either one or two copies of the delF508 CFTR gene mutation.
Ook interessant voor je
